Geneva, Switzerland, September 5, 2018 – Abologix has been selected to participate in the incubation program sponsored by Fondation Eclosion. As part of this program Abologix will receive business, scientific and financial support from Fondation Eclosion. The company will receive 150,000 CHF in the form of a convertible loan.
top of page
Geneva, Switzerland, July 19, 2018 – Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.
Geneva, Switzerland, January 25, 2018 – Abologix, a privately held swiss biotechnology company developing novel immuno-oncology products for the benefit of cancer patients has been founded in Geneva, Switzerland by Dr. Ignacio Faus, Prof. Beat Imhof (University of Geneva) and Prof. Thomas Matthes (Geneva University Hospital ).
bottom of page